Your Twin learns with you

30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Simo Schwartz

Has grant

Senior leading Scientist

Vall d'Hebron Institut de Recerca
Country flagSpain

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Open

Autonomous Scanning Probe Microscopy for Life Sciences and Medicine powered by Artificial Intelligence (SPM4.0)

Open Date: 2025-01-01

Close Date: 2029-01-01

Grant: Open

Smart pathology slide scanner for diagnosis and patient-specific treatment recommendation in oncology (CancerScan).

Open Date: 2025-01-01

Close Date: 2029-01-01

Grant: Close

Breaking Barriers with Remote Integration for Global Pediatric Trials (BRIDGE)

Open Date: 2025-01-01

Close Date:

Grant: Close

Biodegradable and Eco-friendly Smart Hydrogels for the Sustained Intraperitoneal Release of Chemotherapeutics as a Novel Local Therapy Approach for Advanced Ovarian Cancer (HYDROTECH)

Open Date: 2024-01-01

Close Date: 2026-01-01

Grant: Close

EUROPEAN RARE DISEASES RESEARCH ALLIANCE (ERDERA)

Open Date: 2024-01-01

Close Date:

Articles (11)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2023

Year:

2023

Year:

2023

In this study, we developed functionalized polymeric micelles (FPMs) loaded with simvastatin (FPM-Sim) as a drug delivery system to target liver sinusoidal endothelial cells (LSECs) for preserving liver function in chronic liver disease (CLD). Polymeric micelles (PMs) were functionalized by coupling peptide ligands of LSEC membrane receptors CD32b, CD36 and ITGB3. Functionalization was confirmed via spectroscopy and electron microscopy. In vitro and in vivo FPM-Sim internalization was assessed by means of flow cytometry in LSECs, hepatocytes, Kupffer and hepatic stellate cells from healthy rats. Maximum tolerated dose assays were performed in healthy mice and efficacy studies of FPM-Sim were carried out in bile duct ligation (BDL) and thioacetamide (TAA) induction rat models of cirrhosis. Functionalization with the three peptide ligands resulted in stable formulations with a greater degree of in vivo internalization in LSECs than non-functionalized PMs. Administration of FPM-Sim in BDL rats reduced toxicity relative to free simvastatin, albeit with a moderate portal-pressure-lowering effect. In a less severe model of TAA-induced cirrhosis, treatment with FPM-CD32b-Sim nanoparticles for two weeks significantly decreased portal pressure, which was associated with a reduction in liver fibrosis, lower collagen expression as well as the stimulation of nitric oxide synthesis. In conclusion, CD32b-FPM stands out as a good nanotransporter for drug delivery, targeting LSECs, key inducers of liver injury.

Year:

2023

Year:

2023

Collaborators (14)

Ibane Abasolo

-

SPAIN
View details

Bruno Sarmento

Principal Investigator

Cooperativa de Ensino Superior Politécnico e Universitário

PORTUGAL
View details

Higinio Dopeso

Senior Research Scientist

Sloan Kettering Institute

UNITED STATES
View details

Diana Rafael

Vall d'Hebron Research Institute

SPAIN
View details

Manuel Sanchez-Martin

Lecturer

Universidad de Salamanca

SPAIN
View details

María Martell

Vall d'Hebron Institut de Recerca

SPAIN
View details

Xavier Trepat

Research Professor

Instituciò Catalana de Recerca i Estudis Avancats

SPAIN
View details

Laura Mondragon Martinez

Junior Group Leader (Ramón y Cajal contract 2019)

Josep Carreras Leukaemia Research Institute

SPAIN
View details

Simon Clark

Prof. at University of Tübingen

University of Tübingen

GERMANY
View details

Ricard Farré

Professor

Associatie KU Leuven

BELGIUM
View details

Pilar Sánchez-Gómez

Full Professor

Instituto de Salud Carlos III Campus de Majadahonda

SPAIN
View details

Seyed Moein Moghimi

Professor

Newcastle University

UNITED KINGDOM
View details

Fernanda Andrade

Principal Investigator

Universitat Autònoma de Barcelona Facultat de Medicina

SPAIN
View details

Joaquin Seras-Franzoso

Vall d'Hebron Institut de Recerca

SPAIN
View details